Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.
Introduction
Tumor invasion and metastasis are the major catalysts of morbidity and mortality in cancer patients (Haybittle et al., 1982; Rosen and Groshen, 1990) . The initial stages of tumor invasion are characterized by the disruption of cell-cell adhesion, and decreased E-cadherin expression characterizes the invasive phenotype. E-cadherin is a Ca 2 þ -dependent, transmembrane receptor that mediates cell-cell adhesion at adherent junctions through homophilic binding, thus maintaining epithelial cellular adhesion and integrity (Damsky et al., 1983) . There is compelling evidence that E-cadherin expression is repressed in cancer, which suggests that it may have a critical function in the malignant progression of epithelial tumors (Frixen and Nagamine, 1993; Pierceall et al., 1995; Day et al., 1999) . It has been implicated as a tumor suppressor through negative regulation during the course of invasion (Frixen et al., 1991; Hirohashi and Kanai, 2003) . Many epithelial cancer cell lines that lack E-cadherin expression are invasive and administration of exogenous E-cadherin to these cells prevent invasion, suggesting a critical role of this protein in the invasive process (Frixen et al., 1991) . E-cadherin forms dimers, and the cytoplasmic domain of E-cadherin is complexed with catenins that are linked to the actin cytoskeleton network of the cells (Wijnhoven et al., 2000) . The interaction between these molecules regulate the cell-cell adhesion (Halbleib and Nelson, 2006) .
Reduced E-cadherin expression has been linked to metastasis. Numerous studies have demonstrated that aberrant expression of E-cadherin is associated with the development of metastases in breast cancer (Moll et al., 1993; Oka et al., 1993) and gastric cancer (Wu et al., 2005) among others. A number of mechanisms have been suggested for the repression of E-cadherin function during cancer progression including promoter methylation, mutations, transcriptional repression by snail and slug, ubiquitination and degradation of the E-cadherin and lysosomal targeting of the E-cadherin for degradation (Batlle et al., 2000; Fujita et al., 2002; Hajra et al., 2002; Peinado et al., 2004; Saito et al., 2004; Takeno et al., 2004; Palacios et al., 2005) .
Recent studies have shown that histone H3 lysine 27 trimethylation, which is mediated by enhancer of zeste homolog 2 (EZH2) at the promoters of the gene, leads to silencing of gene expression (Chen et al., 2005; Koyanagi et al., 2005; Yu et al., 2007b) . As part of a multi-protein complex with the other members of polycomb-repressive complex 2 (PRC2) (Satijn and Otte, 1999) , EZH2 trimethylates histone H3 tails at lysine 27 (Cao et al., 2002; Kirmizis et al., 2004) . This epigenetic modification is also known to be responsible for X-inactivation (Plath et al., 2003) . Previously, we demonstrated that EZH2 is upregulated in aggressive prostate and breast tumors (Varambally et al., 2002; Kleer et al., 2003) . Several reports have also shown that EZH2 is overexpressed in other aggressive tumors including bronchial cancer (Breuer et al., 2004 ) melanoma (Bachmann et al., 2006) , bladder cancer (Weikert et al., 2005) liver cancer (Sudo et al., 2005) , as well as in vitro cancer cell lines such as SKBR3, MDA-MB-231, T47D breast cell lines (Tan et al., 2007) and the prostate cell lines DU145 and LNCaP (Beke et al., 2007) .
EZH2 is a transcriptional repressor that has a crucial function in maintaining the delicate homeostatic balance between gene expression and repression, the disruption of which may lead to oncogenesis van Lohuizen, 1999, 2002; Sparmann and van Lohuizen, 2006) . Recent studies revealed that EZH2 can physically recruit DNA methyltransferases to certain target genes and silence them, suggesting cross-talk between the two distinct epigenetic silencing mechanisms (Taghavi and van Lohuizen, 2006; Vire et al., 2006) . Cancer cells that contain DNA-methylated genes are specifically packaged in nuclesomes with the histone H3K27 trimethylation (Schlesinger et al., 2007) . Reports also suggest that stem cell polycomb group targets are more likely to exhibit cancer-specific promoter DNA hypermethylation and histone H3 trimethylation of Lys27 relative to non-targets (Ohm et al., 2007; Widschwendter et al., 2007) . In human and mouse embryonic stem cells, as well as in Drosophila, Polycomb Group (PcG) proteins contribute to pluripotency and plasticity through repression of developmental transcriptional factors that normally promote differentiation Bracken et al., 2006; Lee et al., 2006; Tolhuis et al., 2006) .
In this study, we explored the role of histone methylation mediated by PRC2 in the silencing of E-cadherin during cancer progression and provide evidence of a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer development.
Results
Alteration in EZH2 expression changes the invasive phenotype of the cells We have reported earlier that EZH2 expression is increased in aggressive prostate and breast cancer (Varambally et al., 2002; Kleer et al., 2003) . Herein, we evaluated the effect of EZH2 overexpression in multiple primary and non-invasive prostate and breast cells. A modified Boyden chamber assay was used to determine if primary prostate epithelial cells and immortalized breast cell lines (with very low endogenous EZH2 expression) undergo invasion upon ectopic overexpression of EZH2. The epithelial cell lines displayed an invasive phenotype only when infected with an EZH2-encoding adenovirus, and not a control adenovirus ( Figure 1a) . Importantly, EZH2DSET, a truncated version of EZH2 missing the C-terminal SET domain that is required for methyltransferase activity, failed to induce invasion. In addition, EZH2-mediated invasion could be attenuated by incubating cells with the histone deacetylase (HDAC) inhibitor, SAHA, across all of the primary cultures and cell lines tested (Figure 1a ). This suggests a role for histone deacetylation in EZH2-mediated effects.
To expand our investigations, we explored whether perturbation of endogenous EZH2 would affect the invasiveness of cancer cell lines. For these studies, we employed the highly invasive prostate cancer cell line DU145. Overexpression of EZH2DSET in DU145 cells markedly reduced their invasive potential (Figure 1b) , suggesting that this mutant version of EZH2 functioned as dominant negative. Similarly, when EZH2 levels were transiently depleted using siRNA duplexes ( Figure 1c and Supplementary Figure S1a , left panel) or stable knockdown using shRNA ( Figure 1d and Supplementary Figure S1a , right panel), there was marked attenuation of DU145 invasive potential.
EZH2 regulates E-cadherin transcript and protein expression Earlier studies from our group suggested an inverse relationship between EZH2 and E-cadherin expression in prostate cancer (Rhodes et al., 2003) , we hypothesized that EZH2 might regulate E-cadherin in the neoplastic process. We infected an immortalized benign breast epithelial cell line, H16N2, with EZH2, EZH2DSET and control adenoviruses to determine whether EZH2 represses expression of the E-cadherin mRNA transcript. As hypothesized, EZH2 overexpression resulted in abrogation of E-cadherin transcripts as confirmed by two independent methods; northern blot analysis ( Figure 2a ) and quantitative PCR (Figure 2b ). Mutant EZH2 (EZH2DSET) or EZH2-infected cells treated with 500 nM SAHA did not show downregulation of E-cadherin, indicating the importance of the SET domain of EZH2 as well as HDAC activity. The effect of EZH2 overexpression on E-cadherin protein was examined in four cell lines or primary cultures (H16N2, HME, MCF10A and PrEC). We observed marked attenuation of E-cadherin protein levels by EZH2 overexpression, but not EZH2DSET, and not when EZH2 overexpressing cells were treated with HDAC inhibitor SAHA (Figure 2c ). There was dose-dependent inhibition of EZH2-mediated E-cadherin repression when cells were treated with HDAC inhibitors SAHA and trichostatin A (Supplementary Figure S1b) . Immunoblot analysis also showed that E-cadherin repression is dependent on the expression of EZH2; higher EZH2 expression resulting in increased E-cadherin repression (Supplementary Figure S2) . Interestingly, a panel of breast and prostate cell lines showed an inverse correlation of EZH2 and E-cadherin protein expression (Figure 2d ), suggesting that PRC2 may be regulating E-cadherin levels in vivo. Similarly, this inverse associa-EZH2 represses E-cadherin expression Q Cao et al tion between EZH2 and E-cadherin protein levels was recapitulated in situ in both H16N2 breast epithelial cells (Figure 3a ) as well as in breast tumors (Figure 3b ).
E-cadherin expression can rescue EZH2-mediated invasion To determine if E-cadherin loss is a significant factor in the downstream regulation of EZH2-mediated invasion, we re-introduced E-cadherin under the regulation of a CMV promoter. We assessed the possibility that this might counteract the effects of EZH2-mediated silencing of E-cadherin. Although H16N2 cells infected with EZH2 adenovirus were highly invasive and exhibited strong repression of E-cadherin (Figures 1a and 2a) , this was attenuated by overexpression of E-cadherin under a non-EZH2 repressible promoter (that is, CMV) ( Figure 4a ). To confirm that the loss of E-cadherin was a critical step in conferring invasiveness to H16N2 cells, E-cadherin was depleted using siRNA duplexes. H16N2 cells treated with siRNA against E-cadherin acquired invasive potential (Figure 4b ), whereas control siRNA did not show this phenotype. A reconstituted basement membrane invasion chamber assay (Boyden chamber assay) was used to assess the invasive potential of primary prostate and benign breast epithelial cell lines infected with EZH2, EZH2DSET or control adenovirus. EZH2 infected cells were also treated with the histone deacetylase inhibitor SAHA (500 nM). Representative fields of invaded and stained cells are shown (left). Invasion was quantitated using colorimetry (absorbance at 560 nm, right). *P-values were calculated between EZH2 and vector-treated samples, using Student's t-test. (b) The SET domain mutant of EZH2 inhibits cancer cell invasion. DU145 cells, which express high levels of endogenous EZH2, were infected with EZH2, EZH2DSET and control adenoviruses. Invasion was quantitated using colorimetry. *P-values were calculated between EZH2DSET and vectors, using Student's t-test. (c) Cell invasion is attenuated by EZH2 knockdown. Boyden chamber invasion assay using DU145 cells treated with siRNA duplexes targeting EZH2. Inset demonstrates knockdown of EZH2 protein by RNA interference. *P-values were calculated between control and EZH2 knockdown clones, using Student's t-test. (d) Stable knockdown of EZH2 decreases invasiveness of DU145 cells. DU145 cells were stably transfected with EZH2 shRNA and assessed by invasion assay. *P-values were calculated between Control and EZH2 knockdown clones, using Student's t-test. Three stable clones exhibiting knockdown of EZH2 are shown. Inset demonstrates knockdown of EZH2 protein by RNA interference.
EZH2 represses E-cadherin expression Q Cao et al EZH2 regulates the E-cadherin expression by methylating the histone H3 lysine 27 at the promoter region To determine if EZH2 can repress E-cadherin promoter activity, we performed a luciferase assay with an E-cadherin promoter-luciferase reporter construct that contained an endogenous 1.4 KB upstream regulatory region of E-cadherin (Hajra et al., 1999) . As predicted, EZH2 inhibited the activity of the transfected E-cadherin promoter-reporter across all three cell lines tested ( Figure 5a ). EZH2-mediated repression of the E-cadherin promoter was blocked by 500 nM SAHA, highlighting the role of histone deacetylation during EZH2-mediated E-cadherin regulation. Interestingly, the E-cadherin promoter-luciferase reporter was slightly induced by expression of EZH2DSET (Figure 5a ), which suggested a dominant, negative effect. Knockdown of EZH2 in DU145 cells led to increased activity of the transfected E-cadherin promoter-reporter construct ( Figure 5b ). Similarly, when the E-cadherin promoterreporter construct was transfected into stable EZH2 knockdowns or control DU145 cells, the E-cadherin promoter activity was significantly higher in stable EZH2 knockdowns showing an inverse correlation with reduced EZH2 expression (Supplementary Figure S3a) . To determine the minimal region of the E-cadherin promoter required for EZH2-mediated repression, we tested mutant E-cadherin promoter-luciferase reporters (Hajra et al., 2002) including Ecad-EboxA.MUT-luc (mutated Ebox A), Ecad-EboxC.MUT-luc (mutated Ebox C), Ecad-EboxABC.MUT-luc (all the three E-boxes, A, B and C are mutated) as well as wild-type E-cadherin promoter-luciferase reporter. EZH2 repressed 
H16N2
MCF10A HME PrEC Northern blot analysis was carried out using the RNA from H16N2 cells infected with EZH2 and control adenovirus as well as EZH2-infected cells treated with 500 nM SAHA for 48 h. EZH2, E-cadherin and GAPDH probes were labeled with p32dCTP and hybridized to the blots. Note that uninfected H16N2 cells do not express EZH2, whereas E-cadherin is expressed at high levels in these cells. (b) Quantitative SYBR green RT-PCR of EZH2 transcript in cell lines infected with EZH2 and control adenoviruses. RT-PCR on each sample was performed in duplicate, and a ratio was calculated relative to the housekeeping genes GAPDH and hydroxymethylbilane synthase (HMBS). (c) Immunoblot analysis of EZH2 and E-cadherin in breast cell lines H16N2, MCF10A, HME and primary prostate cell PrEC infected with EZH2, EZH2DSET mutant and control adenovirus infected cells as well as EZH2-infected cells treated with 500 nM SAHA for 48 h. b-tubulin was included as a loading control. Experiments were performed three times and a representative immunoblot is shown. (d) Immunoblot analysis of EZH2 and E-cadherin in a panel of breast and prostate cell lines. The cultured lines include both invasive and non-invasive cells. b-tubulin was included as a loading control. Semiquantitation of EZH2 and E-cadherin in multiple cell lines is represented in a graphical format (top panel).
EZH2 represses E-cadherin expression Q Cao et al the wild-type E-cadherin promoter activity and not the E-boxes mutants, indicating the importance of E-box regions in EZH2-mediated E-cadherin repression (Supplementary Figure S3b ). Ectopically overexpressed, myc-tagged EZH2 assembles endogenous PRC2 components including SUZ12 and EED, as demonstrated by their presence in anti-myc immunoprecipitates (Figure 5c ). Addition of 500 nM SAHA did not inhibit the binding of PRC2 complex members, indicating that the HDAC inhibitors do not inhibit PRC2 protein-protein interactions. Furthermore, when we performed immunoprecipitation of endogenous EZH2 and HDAC1, we observed that both EZH2 and HDAC1 interacted with EED (Supplementary Figure S4a ), which confirmed previous findings that EED could interact with HDAC1 (van der Vlag and Figure 4 E-cadherin overexpression attenuates EZH2-mediated cell invasion. (a) H16N2 cells were transfected with E-cadherin or vector alone. Transfected cells were infected with EZH2, EZH2DSET, and control adenovirus. Cell invasion was assessed by Boyden chamber assay, and *P-values were calculated between EZH2 and EZH2 þ E-cadherin samples, using Student's t-test. (b) E-cadherin knockdown in H16N2 cells was carried out using siRNA duplex. siRNA-targeting luciferase served as a control. *P-values were calculated between Luciferease RNAi and EZH2 RNAi samples, using Student's t-test. The inset demonstrates knockdown of E-cadherin protein by RNA interference.
EZH2 represses E-cadherin expression Q Cao et al Otte, 1999 ) and HDAC activity is essential for PRC2. Immunoblot evaluation suggested that the expression of EZH2, EED or HDAC1 did not change in the presence of HDAC inhibitor SAHA (Supplementary Figure S4b) . The polycomb group proteins are known to bind to a selected group of target genes and inhibit transcription Lee et al., 2006) . To determine whether the endogenous PRC2 complex binds to the Ecadherin gene promoter, we carried out chromatin immunoprecipitation (ChIP) assay using antibodies specific to the PRC2 components and to the histone modifications. The invasive prostate cancer cell line DU145, which expresses high level of EZH2 (Figure 2d) , was used to test the complex formation by endogenous EZH2 and other PRC2 complex members. These investigations indicated binding of EZH2, SUZ12 and EED to the E-cadherin promoter (Figure 6a ). In addition, histone H3 was found to be trimethylated at lysine 27 on the E-cadherin promoter. Of particular importance was the finding that the HDAC inhibitor SAHA, although increasing histone acetylation as expected, markedly reduced PRC2 occupancy and H3K27 trimethylation on the E-cadherin promoter. To preclude nonspecific enrichment by ChIP, multiple negative controls were used, including the IgG antibody control, NUP214 negative gene control, as well as relative controls for the same antibody enrichment between SAHA-treated and untreated samples. Furthermore, we observed that HDAC1 was recruited to the promoter region of E-cadherin as well, indicating a role for HDAC1 in regulating the promoter activity. The presence of HDAC1 inhibitor SAHA significantly reduced HDAC1 occupancy on E-cadherin promoter region (Supplementary Figure S4c) suggesting that histone deacetylation may be a prerequisite for EZH2-mediated repression of E-cadherin expression.
As ectopic EZH2 assembles the PRC2 complex (Figure 5c ), we explored the possibility that it might recruit the PRC2 complex proteins to the E-cadherin promoter.
The H16N2 immortalized breast epithelial cell line, which has low level of endogenous EZH2, was infected with either vector control or EZH2 adenovirus and examined for PRC2 occupancy on the E-cadherin promoter. Using an antibody against myc epitope, tagged at both EZH2 and mutant EZH2 constructs, we confirmed by ChIP that ectopically expressed EZH2, but not the vector or mutant EZH2, binds to the E-cadherin promoter (Figure 6b and Supplementary Figure S4d ). This binding can be mitigated by the HDAC inhibitor SAHA. Concordantly, ChIP-PCR demonstrated significant (Po0.001) enrichment of EZH2 binding and H3K27 trimethylation on the E-cadherin promoter by EZH2 overexpression (Figure 6b and Supplementary Figure S4d) .
Next we attempted to examine H3K27 trimethylation on the E-cadherin promoter in vivo in EZH2-high Figure 5 EZH2 regulates E-cadherin promoter activity. (a) Benign breast cell lines H16N2, MCF10A and HME were transfected with an E-cadherin-luciferase promoter construct and infected with either EZH2, EZH2DSET or control adenovirus. EZH2-infected cells were also incubated with 500 nM SAHA. Relative luciferase activity (RLA) was assessed. *P-values were calculated between EZH2 overexpression and vector control using Student's t-test. (b) Knockdown of EZH2 in DU145 cells induces E-cadherin promoter activity. EZH2 expression was inhibited by RNA interference in DU145 cells that were transfected with the E-cadherin promoter-luciferase construct. *P-value was calculated between EZH2 RNAi and scrambled RNAi samples, using Student's t-test.
(c) Ectopically expressed EZH2 functions in a complex with endogenous PRC2 components SUZ12 and EED. H16N2 cells were infected with myc-tagged EZH2 and control adenovirus as well as EZH2-infected cells treated with 500 nM SAHA for 48 h. Immunoprecipitation was carried out using anti-myc antibody, and subsequent western blotting performed with either SUZ12 or EED antibody.
EZH2 represses E-cadherin expression Q Cao et al metastatic prostate tumors. ChIP combined with ligation-mediated PCR, as described earlier (Yu et al., 2007b) , was used to detect the enrichment of target genomic region by an antibody against H3K27 trimethylation, relative to the input DNA. Remarkably, a hundred-fold enrichment of H3K27 trimethylation on the E-cadherin promoter was detected (Figure 6c ). This enrichment was also detected in a previously characterized PRC2 target gene WNT1, but not in the NUP214 negative control gene (Supplementary Figure S4e) . By contrast, analysis of an EZH2-low localized prostate tumor showed significantly less enrichment (Po0.001) of the E-cadherin promoter for H3K27 trimethylation. Subsequently, we attempted to test if DNA methylation has any role in EZH2-mediated E-cadherin repression. E-cadherin promoter DNA methylation analysis using EZH2 overexpressing cells by bisulfite modification and methylation-specific PCR as well as pyrosequencing did not exhibit E-cadherin promoter DNA methylation (Supplementary Figure S5a-e) . The endogenous PRC2 complex is recruited to the E-cadherin promoter. Chromatin immunoprecipitation (ChIP) was carried out using antibodies against EZH2, EED, SUZ12, trimethyl-histone H3-Lys27 (3mH3K27), acetyl histone H3 (Ac-H3) and IgG control. Addition of 500 nM SAHA curtails the recruitment of these complexes to the E-cadherin promoter, whereas acetylated histone levels increase at the E-cadherin promoter. Each chromatin immunoprecipitation (ChIP) experiment was repeated at least three times and a representative experiment is shown. (b) Ectopically expressed EZH2 binds the E-cadherin promoter and leads to H3K27 trimethylation. ChIP was carried out in H16N2 cells infected with EZH2 or control adenovirus and assayed by PCR analysis. The upper panel shows in the cells overexpressing myc-tagged EZH2 constructs, EZH2 was found to bind the E-cadherin promoter. The lower panel showed by qPCR that EZH2 and 3mH3K27 co-occupy the E-cadherin promoter in the EZH2-overexpressing H16N2 cells. The enrichments in EZH2-overexpressing cells are significantly (Po0.001) higher than those in the vector-treated cells. Error bar: n ¼ 3, mean±s.e.m. (c) The E-cadherin promoter contains significantly (Po0.001) more H3K27 trimethylation in metastatic prostate cancer tissues (MET) relative to localized prostate cancer (PCa). ChIP experiments were performed using anti-3mH3K27 antibody in one localized prostate tumor and three independent metastatic prostate tumors. ChIP-enriched DNA and the input DNA were first amplified through ligation-mediated PCR. Equal amounts (50 ng) of amplified ChIP DNA and the input DNA were then subjected to PCR, and enrichment by ChIP was assessed relative to the input DNA and normalized to the level of GAPDH. Error bar: n ¼ 3, mean ± s.e.m. (d) A model depicting the mechanism of EZH2-mediated E-cadherin repression. In benign cells the E-cadherin promoter is not occupied by PRC2 complex. In cancer, the increased expression of PRC2 leads to tight binding to the promoter of E-cadherin, followed by deacetylation of histone H3 and subsequent trimethylation of lysine 27. This leads to repression of E-cadherin expression. The addition of HDAC inhibitors prevents the first step of histone deacetylation, and hence the EZH2 complex cannot methylate histone H3.
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Recently, it has been shown that DNA methyltransferases and EZH2 cooperate in silencing genes such as MYT1, WNT1, KCNA1 and CNR1 (Vire et al., 2006) . In addition, H3K9 methylation may lead to promoter CpG island DNA methylation (Ohm et al., 2007) . However our study indicated that there was no alteration in the DNA methylation status of E-cadherin promoter upon EZH2 overexpression. This indicated that histone trimethylation mediated by EZH2 has a key function in the silencing of E-cadherin.
Discussion
In the present study, we describe a novel mechanism by which E-cadherin is downregulated in EZH2-overexpressing cells through histone H3K27 trimethylation at the E-cadherin promoter. Although EZH2 expression was low in benign epithelial tissues, the expression of EZH2 increased with tumor progression. EZH2 expression became dysregulated concurrently with increased HDAC activity, which resulted in trimethylation of histone H3 lysine 27 at the E-cadherin promoter with subsequent repression of expression (Figure 6d ). This enzymatic activity was inhibited, however, when the cells were treated with HDAC inhibitor despite overexpression of EZH2.
A large body of evidence suggests that loss of E-cadherin expression is associated with the acquisition of invasiveness and advanced tumor stage for cancers of epithelial origin including prostate (Umbas et al., 1994 (Umbas et al., , 1997 , gastric (Mayer et al., 1993) , colon (Dorudi et al., 1995) and breast cancer (Oka et al., 1993; Rasbridge et al., 1993; Palacios et al., 1995) . EZH2 is also known to increase the proliferation and invasiveness of prostate cells (Bryant et al., 2007) and our study indicates the role of E-cadherin in EZH2-mediated cell invasion. Although several mechanisms have been proposed for the downregulation of E-cadherin, our data suggest a novel mechanism whereby increased levels of EZH2 in aggressive tumors silence E-cadherin expression through histone H3K27 trimethylation. EZH2 regulates E-cadherin transcription by physically binding to its promoter. The expression of EZH2 enhances HDAC activity (Kleer et al., 2003) and we hypothesize that increased HDAC activity leads to the removal of the acetyl group from the histone H3K27 at the promoter region of E-cadherin. This enables EZH2 to exert its histone methyltransferase enzymatic activity. Recent studies by (Fujii and Ochiai (2008) indicate that in gastric cancer, EZH2 downregulates E-cadherin expression by histone modification. Tri-methylation of histone H3 on lysine 27 leads to compaction of chromatin and blocks transcription factors from binding and initiating transcription. EZH2 may mediate increased invasiveness and metastasis by silencing a number of downstream targets in addition to E-cadherin including b adrenergic receptor ADRB2 (Yu et al., 2007a) . Interestingly, our observations indicate that DNA methylation does not have a function in EZH2-mediated repression of E-cadherin expression. A recent study by Kondo et al. (2008) suggests that gene silencing by histone H3 lysine K27 trimethylation is independent of promoter DNA methylation.
Further, we demonstrated that HDAC inhibitors inhibited the activity of EZH2 and prevented the EZH2-mediated downregulation of E-cadherin, as well as reduced the invasion, suggesting a mechanism for these anti-cancer drugs. We propose that EZH2 acts on deacetylated histone to methylate the lysine residue. However, inhibition of deacetylases prevents the removal of acetyl groups from lysine residues of histones. Acetylated lysine residues in histones will not serve as a substrate for methylation by EZH2. In addition, our findings suggest that EZH2 may be a viable target for therapeutic inhibition in aggressive tumors of epithelial origin. Our findings identify a molecular mechanism by which EZH2 mediates transcriptional repression of E-cadherin and provide insight into EZH2-mediated invasion and metastasis.
Materials and methods

Basement membrane matrix invasion assay
For invasion assays, the breast cell lines H16N2, HME and MCF10A (ATCC, Manassas, VA, USA), as well as normal prostate epithelial cells (PrEC, Cambrex, East Rutherford, NJ, USA), were infected with vector, EZH2 and EZH2DSET adenovirus. Forty-eight hours post-infection, cells were seeded onto the basement membrane matrix (EC matrix, Chemicon, Temecula, CA, USA) present in the insert of a 24-well culture plate. Fetal bovine serum was added to the lower chamber as a chemoattractant with or without 500 nM HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (Biovision Inc., Mountain View, CA, USA). After 48 h, the non-invading cells and EC matrix were gently removed with a cotton swab. Invasive cells located on the lower side of the chamber were stained with crystal violet, air-dried and photographed. They were then enumerated microscopically using multiple representative areas. For colorimetric assays, the inserts were treated with 150 ml of 10% acetic acid and the absorbance measured at 560 nm using a spectrophotometer (GE Healthcare Life Sciences, Piscataway, NJ, USA).
RNA interference
The knockdown of EZH2 was accomplished with either siRNA duplex (Dharmacon, Lafayette, CO, USA) as described earlier (Varambally et al., 2002) or shRNA expression vectors (Open Biosystems, Huntsville, AL, USA). E-cadherin knockdown was performed using siRNA duplex. (Dharmacon)
Immunoblot analyses
The breast cell lines H16N2, HME and MCF10A, as well as normal prostate epithelial cells, were grown to 60% confluency and infected with either EZH2, vector control or EZH2DSET adenovirus for 48 h. An additional set of cells were infected with EZH2 adenovirus and treated with 500 nM HDAC inhibitor SAHA (Biovision, Mountain View, CA, USA) for 48 h. Cells were homogenized in NP40 lysis buffer (50 mM Tris-HCl, 1% NP40, pH 7.4, Sigma, St Louis, MO, USA), and complete proteinase inhibitor mixture (Roche, Indianapolis, IN, USA). Ten micrograms of each protein extract were boiled EZH2 represses E-cadherin expression Q Cao et al in sample buffer, separated by SDS-PAGE, and transferred onto Polyvinylidene Difluoride membrane (GE Healthcare). The membrane was incubated for 1 h in blocking buffer (Tris-buffered saline, 0.1% Tween (TBS-T), 5% nonfat dry milk) and incubated overnight at 4 1C with the following: anti-EZH2 mouse monoclonal (1:1000, 1:5000 in dilution buffer, BD Biosciences, San Jose, CA, USA no. 612666), anti-E-CAD mouse monoclonal antibodies (1:1000, 1:5000 in dilution buffer, BD Biosciences, no. 610405), anti-EED rabbit polyclonal antibody (1:1000 in dilution buffer, Upstate, Charlottesville, VA, USA no. 07-368), anti-SUZ12 rabbit polyclonal antibody (1:1000 in dilution buffer, kind gift from Professor Otte), and HDAC1 monoclonal antibody (1:1000 in dilution buffer, Millipore, #05-614). Following a wash with TBS-T, the blot was incubated with horseradish peroxidase-conjugated secondary antibody and the signals visualized by enhanced chemiluminescence system as described by the manufacturer (GE Healthcare). The blot was re-probed with b-tubulin for confirmation of equal loading.
Northern blot analyses
Total RNA was isolated from H16N2 cells that were infected with either vector, EZH2, or EZH2DSET adenovirus for 48 h. An additional set of cells were infected with EZH2 adenovirus and were treated with 500 nM HDAC inhibitor SAHA (Biovision, Mountain View, CA, USA) for 48 h. Twenty micrograms of total RNA from each condition were resolved on a denaturing formaldehyde agarose gel and subsequently transferred onto a Hybond-NX membrane (Amersham Biosciences, Piscataway, NJ, USA). EZH2, E-cadherin and GAPDH probes were labeled with p32dCTP (GE Healthcare) and hybridized to the blots. The signal was visualized and quantified using a Typhoon Scanner 9000B and Image Quant Software (Amersham Biosciences). E-cadherin and EZH2 signals were normalized to that of GAPDH.
SYBR green quantitative real-time PCR Total RNA was isolated from H16N2 cells that were infected either with vector, EZH2 or EZH2DSET adenovirus. Quantitative PCR (QPCR) was performed using SYBR Green dye on an Applied Biosystems 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Briefly, 1 mg of total RNA was reverse transcribed into cDNA using SuperScript III (Invitrogen, Carlsbad, CA, USA) in the presence of random hexamers and oligo dT primers (Invitrogen). All reactions were performed in duplicate with SYBR Green Master Mix (Applied Biosystems) plus 25 ng of both the forward and reverse primer according to the manufacturer's recommended thermocycling conditions, and then subjected to melt curve analysis. Threshold levels for each experiment were set during the exponential phase of the QPCR using Sequence Detection Software version 1.2.2 (Applied Biosystems). The DNA in each sample was quantified by interpolation of its threshold cycle (C t ) value from a standard curve of C t values, which were created from a serially diluted cDNA mixture of all samples. The calculated quantity of the target gene for each sample was divided by the average sample quantity of the housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hydroxymethylbilane synthase (HMBS) to obtain the relative gene expression. All oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Primers for HMBS and GAPDH were as described (Vandesompele et al., 2002) . Primers for CDH1 were: CDH1-F, 5 0 -GGAGGAGAGCGGTGGTCAAA-3 0 ; CDH1-R, 5 0 -TG TGCAGCTGGCTCAAGTCAA-3 0 .
Immunofluorescence H16N2 cells were grown using chamber slides (Nunc, Rochester, NY, USA) and infected with either control or EZH2 virus for cell line co-immunostaining with EZH2 and E-cadherin antibody. Forty-eight hours post-infection, the slides were washed with PBS and were fixed using ice-cold methanol. Following an additional PBS wash, the slides were blocked for two hours using 5% donkey serum in PBS-T (phosphate-buffered saline, 0.05% Tween 20). A mixture of rabbit anti-E-cadherin antibody (Labvision, Fremont, CA, USA no. RB-9214-P) and mouse anti-EZH2 antibody (BD Biosciences, San Jose, CA, USA) were added to the slides at 1:250 and 1:100 dilutions, respectively, and incubated overnight at 4 1C. Following an additional wash, the slides were incubated with Alexa 555-conjugated goat, anti-rabbit antibody and Alexa 488-conjugated goat, anti-rabbit secondary antibody (Invitrogen) for 1 h in the dark at room temperature. After washing, the slides were mounted using Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingam, CA, USA). Breast tissues samples were collected with informed consent and prior institutional review board approval. To prepare for tissue section staining, paraffin-embedded breast tissue slides were soaked in xylene for 1 h removal of paraffin. Slides were placed in citrate buffer (pH 6.0) and heated under pressure for 15 min for antigen retrieval. They were then blocked in PBS-T with 5% normal donkey serum for 1 h. A mixture of rabbit anti-E-cadherin antibody (Labvision) and mouse anti-EZH2 antibody (BD Biosciences) was added to the slides at 1:250 and 1:100 dilutions respectively and incubated overnight at 4 1C. Slides were then incubated with secondary antibodies for 1 h (anti-mouse IgG horseradish peroxidase conjugate and antirabbit Alexa 555, both at 1:1000 dilution). Following a wash, fluorescently-labeled tyramide (Alexa Fluor 488, Invitrogen) was added and the slides incubated for 10 min at room temperature. They were washed and then mounted using Vectashield mounting medium. Confocal images were taken with a Zeiss LSM510 META imaging system using Argon and Helium Neon 1 and Helium Neon 2 light source (Carl Zeiss, Thornwood, NY, USA). The color images were exported as TIFF images.
Luciferase assay E-cadherin regulation by EZH2 was examined using the E-cadherin promoter-luciferase reporter gene and transient transfection assays were performed. The breast cell lines H16N2, MCF10A and HME were transfected with wild-type or E-box mutant E-cadherin luciferase construct (kind gift of Dr Eric Fearon) as well as pRL-TK vector as internal control for luciferase activity, then subsequently infected with either EZH2 or control viruses. Following 2 days of incubation, the cells were lysed and luciferase assays conducted using the dual luciferase assay system (Promega, Madison, WI, USA). Each experiment was performed in triplicate. Using siRNA duplex, an EZH2 knockdown was performed in the invasive prostate cell line DU145. Both were simultaneously transfected with E-cadherin promoter-luciferase reporter constructs, and the luciferase activity was measured after 2 days as described earlier.
Chromatin immunoprecipitation assay
ChIP experiments were carried out as described by Yu et al. (2007a) . For each ChIP assay, 5 ug of antibodies were used; EZH2 (BD Biosciences, no. 612666), SUZ12 (Abcam, Cambridge, MA, USA no. ab12201), EED (Upstate, no. 07-368), trimethyl H3-Lys27 (Upstate, no. 07-449) and acetyl H3 (Upstate, no. 06-599), Myc (Abcam, no. ab32), HDAC1 (Milipore, no. 17-608) or IgG control (Santa Cruz, no. 12-370). Approximately 2-5 ml of ChIP-enriched chromatins EZH2 represses E-cadherin expression Q Cao et al were subjected to a standard ChIP-PCR, and the enrichment of specific genomic regions was assessed relative to either control IgG or control cells. Each ChIP experiment was repeated at least three times. For ChIP with human tissues, ChIP-enriched DNA and input DNA were amplified through ligation-mediated PCR. Equal amounts (50 ng) of amplified ChIP DNA and input DNA were subjected to PCR. Enrichment by ChIP was assessed relative to the input DNA and normalized to the level of GAPDH. The primers used in the ChIP experiments were designed to flank the promoter regions of CDH1 and the WNT1-positive control gene, as well as the intragenic region of the NUP214 negative control. The sequences of the primers were: CDH1-pF,TAGAGGGTCA CCGCGTCTAT; CDH1-pR, TCACAGGTGCTTTGCAGT TC; WNT1-pF1, ACCCGTCAGCTCTCGGCTCA; WNT1-pR1, TGCAGTTGCGGCGACTTTGG; NUP214_pF1, CAG TGAGGTCTCAGCATCAGCA; NUP214_pR1, CTGGAG GCTATGGGGGTACTTG.
